Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.

@article{Petrioli2015SwitchMT,
  title={Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.},
  author={Roberto Petrioli and Edoardo Francini and Anna Ida Fiaschi and Letizia Laera and Luca Luzzi and Piero Paladini and Claudia Ghiribelli and Luca Voltolini and Vincenzo Bianco and Giandomenico Roviello},
  journal={Medical oncology},
  year={2015},
  volume={32 4},
  pages={134}
}
The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevacizumab (Bev), followed by maintenance treatment with Bev and oral vinorelbine (Vnb), in patients with advanced non-squamous non-small cell lung cancer (NSCLC). The patients were administered six cycles of induction chemotherapy consisting of intravenously (i.v… CONTINUE READING